- Home
- WEA vs SPRO Comparison
WEA vs SPRO Comparison
Compare WEA & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- SPRO
- Stock Information
- Founded
- WEA 2002
- SPRO 2013
- Country
- WEA United States
- SPRO United States
- Employees
- WEA N/A
- SPRO N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- WEA Finance
- SPRO Health Care
- Exchange
- WEA Nasdaq
- SPRO Nasdaq
- Market Cap
- WEA 129.6M
- SPRO 123.0M
- IPO Year
- WEA N/A
- SPRO 2017
- Fundamental
- Price
- WEA $10.91
- SPRO $1.91
- Analyst Decision
- WEA
- SPRO Buy
- Analyst Count
- WEA 0
- SPRO 4
- Target Price
- WEA N/A
- SPRO $5.00
- AVG Volume (30 Days)
- WEA 46.1K
- SPRO 814.6K
- Earning Date
- WEA 01-01-0001
- SPRO 08-12-2025
- Dividend Yield
- WEA 7.87%
- SPRO N/A
- EPS Growth
- WEA N/A
- SPRO N/A
- EPS
- WEA N/A
- SPRO N/A
- Revenue
- WEA N/A
- SPRO $48,576,000.00
- Revenue This Year
- WEA N/A
- SPRO N/A
- Revenue Next Year
- WEA N/A
- SPRO N/A
- P/E Ratio
- WEA N/A
- SPRO N/A
- Revenue Growth
- WEA N/A
- SPRO N/A
- 52 Week Low
- WEA $9.60
- SPRO $0.51
- 52 Week High
- WEA $11.29
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- WEA 56.73
- SPRO 35.03
- Support Level
- WEA $10.82
- SPRO $2.15
- Resistance Level
- WEA $10.95
- SPRO $2.38
- Average True Range (ATR)
- WEA 0.07
- SPRO 0.15
- MACD
- WEA 0.01
- SPRO -0.03
- Stochastic Oscillator
- WEA 78.95
- SPRO 10.26
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.